MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product for preliminary screening of HIV and hepatitis. It also provides the Miriad RVF toolkit, which facilitates the development and commercialization of rapid diagnostics; and REVEALCOVID-19 and Reveal G4 HIV tests. The company distributes its products through a network of medical distributors and strategic business development partners, serving customers in various healthcare sectors, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.
Metrics to compare | MIR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMIRPeersSector | |
---|---|---|---|---|
P/E Ratio | −11.3x | −5.4x | −0.5x | |
PEG Ratio | 0.28 | −0.28 | 0.00 | |
Price/Book | −2.4x | 1.0x | 2.6x | |
Price / LTM Sales | 207.0x | 28.5x | 3.3x | |
Upside (Analyst Target) | - | 242.2% | 43.4% | |
Fair Value Upside | Unlock | −10.3% | 7.1% | Unlock |